$1.52 Billion is the total value of Casdin Capital, LLC's 37 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ILMN | New | ILLUMINA INC | $73,454,000 | – | 385,000 | +100.0% | 4.82% | – |
| NTLA | New | INTELLIA THERAPEUTICS INC | $16,508,000 | – | 295,000 | +100.0% | 1.08% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $15,668,000 | – | 750,000 | +100.0% | 1.03% | – |
| ARVN | New | ARVINAS INC | $8,898,000 | – | 200,000 | +100.0% | 0.58% | – |
| MRTX | New | MIRATI THERAPEUTICS INCcall | $6,984,000 | – | 100,000 | +100.0% | 0.46% | – |
| MRNA | New | MODERNA INC | $3,843,000 | – | 32,500 | +100.0% | 0.25% | – |
| CERE | New | CEREVEL THERAPEUTICS HLDNG I | $2,261,000 | – | 80,000 | +100.0% | 0.15% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 35 | Q2 2024 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 35 | Q2 2024 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| FATE THERAPEUTICS INC | 27 | Q4 2023 | 8.3% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| BIOLIFE SOLUTIONS INC | 25 | Q2 2024 | 14.9% |
| CODEXIS INC | 25 | Q2 2024 | 8.1% |
| SAREPTA THERAPEUTICS INC | 24 | Q2 2024 | 13.6% |
| ILLUMINA INC | 24 | Q2 2024 | 6.0% |
| DENALI THERAPEUTICS INC | 23 | Q2 2024 | 3.7% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Century Therapeutics, Inc. | April 18, 2024 | 5,190,506 | 6.1% |
| MAXCYTE, INC.Sold out | February 14, 2024 | 0 | 0.0% |
| Relay Therapeutics, Inc. | February 14, 2024 | 7,387,943 | 6.0% |
| EQRx, Inc.Sold out | November 15, 2023 | 0 | 0.0% |
| BIOLIFE SOLUTIONS INC | October 24, 2023 | 8,707,165 | 19.5% |
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-29 |
| 4 | 2024-08-26 |
| 4 | 2024-08-21 |
| 4 | 2024-08-16 |
| 13F-HR | 2024-08-14 |
| SC 13D/A | 2024-08-14 |
| 4 | 2024-08-13 |
| 4 | 2024-08-09 |
| 4 | 2024-08-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.